Mei-Yin Chen Polley, PhD

Dr. Polley’s primary research involves the design, conduct, and analysis of all phases of cancer clinical trials. She is the Head of the Statistics Division of NRG Oncology Statistics and Data Management Center (SDMC) as well as the Co-Chair of the Brain Tumor Committee of NRG Oncology, a National Cancer Institute sponsored member of the national clinical trials network group. Previously, she served as the Director of the Biostatistics and Bioinformatics Core of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE). Dr. Polley had served on many scientific governing or advisory bodies including the National Cancer Institute Steering Committees (breast, lymphoma, head and neck cancer, and pediatric and adolescent solid tumor), the Scientific Program Committee of American Society of Clinical Oncology (ASCO) annual meetings, and the US Veterans Affairs (VA) Oncology A Study Section. Dr. Polley’s methodological interests include early-phase clinical trial designs, biomarker reproducibility, innovative group sequential methods for biomarker validation, prognostic and predictive modeling, design and analysis of biomarker-based clinical trials, and design and monitoring of late phase clinical trials.

Columbia University
New York, New York
PhD - Biostatistics
2006

Columbia University
New York, New York
MS - Biostatistics
2001

Harvard University
Cambridge, Massachusetts
MA - Statistics
1999

Leveraging External Control Data in the Design and Analysis of Neuro-Oncology Trials: Pearls and Perils.
Leveraging External Control Data in the Design and Analysis of Neuro-Oncology Trials: Pearls and Perils. Neuro Oncol. 2024 Jan 22.
PMID: 38254183

Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076.
PMID: 37944590

NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad116.
PMID: 38024244

Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330.
PMID: 37385460

Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along.
Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along. Am Soc Clin Oncol Educ Book. 2023 May; 43:e389322.
PMID: 37167580

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 2023 04; 24(4):e161-e171.
PMID: 36990614

Reply to B. Zhao et al.
Reply to B. Zhao et al. J Clin Oncol. 2023 02 01; 41(4):934-935.
PMID: 36191279

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol. 2022 08 10; 40(23):2539-2545.
PMID: 35731991

On the Quest of Risk Stratification in HER2-Positive Breast Cancer.
On the Quest of Risk Stratification in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2022 03 08; 114(3):345-346.
PMID: 33787921

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.
PMID: 35044810

View All Publications

Appointee - Special Government Employee (SGE) member, Federal Advisory Committee Act (FACA)
US Department of Veterans Affairs (VA)
2021 - 2025

Breast Cancer Specialized Program of Research Excellence - Developmental Research Program Award
Mayo Clinic
2018

The Fraternal Order of Eagles Cancer Research Award
Mayo Clinic Cancer Center
2017

Distinguished Achievement Award
Kelly Government Solutions, National Cancer Institute
2012

Award for Excellence in Clinical Research
The American Brain Tumor Association
2009

REAC Pilot Research Award in Basic and Clinical/Translational Sciences
University of California San Francisco
2009

Travel Award - Biostatistics Workshop
American Association for Cancer Research (AACR)
2008

The Joseph L. Fleiss Memorial Prize in Biostatistics for an Outstanding Dissertation
Columbia University
2006

Merck & Co., Inc. Fellowship
Columbia University
2001 - 2004